Although it has been shown that, 2 weeks continuous subcutaneous insulin infusion (CSII) achieved good glycemic control and resulted in an improvement in lipid parameters in newly diagnosed type 2 diabetic patients with fasting glucose levels >200 mg/dl[13], the effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients has not been established. This evidence concerns the gene INS and type 2 diabetes mellitus.